Waldencast issued a press release reporting its financial results for the second quarter of 2025 on November 24, 2025. The Company updated its financial outlook for the full year of 2025, expecting net revenue to be broadly in line with 2024 and adjusted EBITDA margin in the high single digits. Previously, Waldencast had guided to mid-teens net revenue growth and an adjusted EBITDA margin in the mid-to-high teens. The Company also reported a net loss of $185.2 million for the first half of 2025, primarily driven by impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, respectively.
Following this news, Waldencast's share price fell over 6% on November 24, 2025.
To receive more information, please fill out the form.
